MARINUS PHARMACEUTICALS INC (MRNS)
US56854Q2003 - Common Stock
We assign a fundamental rating of 2 out of 10 to MRNS. MRNS was compared to 191 industry peers in the Pharmaceuticals industry. MRNS may be in some trouble as it scores bad on both profitability and health. MRNS is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
MRNS had negative earnings in the past year.
MRNS had a negative operating cash flow in the past year.
MRNS had negative earnings in each of the past 5 years.
In the past 5 years MRNS always reported negative operating cash flow.
1.2 Ratios
MRNS's Return On Assets of -220.81% is on the low side compared to the rest of the industry. MRNS is outperformed by 90.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -220.81% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-54.19%
ROA(5y)-53.62%
ROE(3y)-348.39%
ROE(5y)-232.49%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 90.17%, MRNS belongs to the top of the industry, outperforming 92.93% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for MRNS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 90.17% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MRNS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MRNS has more shares outstanding
MRNS has more shares outstanding than it did 5 years ago.
MRNS has a worse debt/assets ratio than last year.
2.2 Solvency
MRNS has an Altman-Z score of -20.06. This is a bad value and indicates that MRNS is not financially healthy and even has some risk of bankruptcy.
MRNS has a worse Altman-Z score (-20.06) than 86.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -20.06 |
ROIC/WACCN/A
WACC11.48%
2.3 Liquidity
MRNS has a Current Ratio of 1.66. This is a normal value and indicates that MRNS is financially healthy and should not expect problems in meeting its short term obligations.
MRNS's Current ratio of 1.66 is on the low side compared to the rest of the industry. MRNS is outperformed by 66.85% of its industry peers.
MRNS has a Quick Ratio of 1.47. This is a normal value and indicates that MRNS is financially healthy and should not expect problems in meeting its short term obligations.
MRNS has a Quick ratio of 1.47. This is in the lower half of the industry: MRNS underperforms 65.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.47 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 7.92% over the past year.
Looking at the last year, MRNS shows a small growth in Revenue. The Revenue has grown by 1.63% in the last year.
The Revenue has been growing by 162.16% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)7.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.15%
Revenue 1Y (TTM)1.63%
Revenue growth 3Y162.16%
Revenue growth 5YN/A
Sales Q2Q%16.39%
3.2 Future
MRNS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.24% yearly.
Based on estimates for the next years, MRNS will show a very strong growth in Revenue. The Revenue will grow by 36.78% on average per year.
EPS Next Y21.6%
EPS Next 2Y33.44%
EPS Next 3Y23.5%
EPS Next 5Y18.24%
Revenue Next Year8.79%
Revenue Next 2Y25.16%
Revenue Next 3Y22.81%
Revenue Next 5Y36.78%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MRNS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRNS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as MRNS's earnings are expected to grow with 23.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.44%
EPS Next 3Y23.5%
5. Dividend
5.1 Amount
MRNS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MARINUS PHARMACEUTICALS INC
NASDAQ:MRNS (1/3/2025, 8:00:01 PM)
After market: 0.5307 -0.01 (-1.36%)0.538
+0 (+0.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners78.71%
Inst Owner Change-4.52%
Ins Owners0.66%
Ins Owner Change-0.81%
Market Cap29.69M
Analysts73.85
Price Target2.74 (409.29%)
Short Float %8.8%
Short Ratio1.13
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.15%
Min EPS beat(2)-0.53%
Max EPS beat(2)0.22%
EPS beat(4)1
Avg EPS beat(4)-4.39%
Min EPS beat(4)-16.47%
Max EPS beat(4)0.22%
EPS beat(8)4
Avg EPS beat(8)1.33%
EPS beat(12)6
Avg EPS beat(12)-24.79%
EPS beat(16)8
Avg EPS beat(16)-20.52%
Revenue beat(2)0
Avg Revenue beat(2)-13.95%
Min Revenue beat(2)-16.82%
Max Revenue beat(2)-11.09%
Revenue beat(4)0
Avg Revenue beat(4)-14.36%
Min Revenue beat(4)-17.5%
Max Revenue beat(4)-11.09%
Revenue beat(8)4
Avg Revenue beat(8)8.04%
Revenue beat(12)5
Avg Revenue beat(12)33.61%
Revenue beat(16)7
Avg Revenue beat(16)46.44%
PT rev (1m)-5.76%
PT rev (3m)-61.01%
EPS NQ rev (1m)0%
EPS NQ rev (3m)45%
EPS NY rev (1m)0.05%
EPS NY rev (3m)-6.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.45%
Revenue NY rev (1m)-1.56%
Revenue NY rev (3m)-6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.94 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.44
EYN/A
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)-2.1
FCFYN/A
OCF(TTM)-2.08
OCFYN/A
SpS0.57
BVpS-1.21
TBVpS-1.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -220.81% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 90.17% | ||
| FCFM | N/A |
ROA(3y)-54.19%
ROA(5y)-53.62%
ROE(3y)-348.39%
ROE(5y)-232.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 224.53% | ||
| Cap/Sales | 3.75% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.47 | ||
| Altman-Z | -20.06 |
F-Score2
WACC11.48%
ROIC/WACCN/A
Cap/Depr(3y)415.27%
Cap/Depr(5y)277.02%
Cap/Sales(3y)8.72%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.15%
EPS Next Y21.6%
EPS Next 2Y33.44%
EPS Next 3Y23.5%
EPS Next 5Y18.24%
Revenue 1Y (TTM)1.63%
Revenue growth 3Y162.16%
Revenue growth 5YN/A
Sales Q2Q%16.39%
Revenue Next Year8.79%
Revenue Next 2Y25.16%
Revenue Next 3Y22.81%
Revenue Next 5Y36.78%
EBIT growth 1Y2.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.8%
OCF growth 3YN/A
OCF growth 5YN/A